(Hypertension. 1996;28:464-471.)
© 1996 American Heart Association, Inc.
Articles |
Effects of an Angiotensin-Converting Enzyme Inhibitor, a Calcium Antagonist, and an Endothelin Receptor Antagonist on Renal Afferent Arteriolar Structure
the Department of Pathology, Aarhus University Hospital (K.S.), and Department of Pharmacology, University of Aarhus (J.F.-G., M.J.M.) (Denmark).
Narrowed afferent arteriolar diameter in young, spontaneously hypertensive rats (SHR) may be a contributor to later development of high blood pressure. Thus, treatment that causes dilation of the afferent arterioles in SHR may inhibit the redevelopment of high blood pressure when treatment is withdrawn. We treated SHR with an ACE inhibitor (cilazapril, 5 to 10 mg/kg per day, high; 1 mg/kg per day, low), a calcium antagonist (mibefradil, 20 to 30 mg/kg per day), and an endothelin receptor antagonist (bosentan, 100 mg/kg per day) from age 4 to 20 weeks. Untreated SHR and Wistar-Kyoto rats were also investigated. At 20 weeks, the rats were killed, and morphology of the afferent arterioles was studied. Other SHR (untreated, high cilazapril, low cilazapril, mibefradil) were treated in exactly the same way and then followed to 32 weeks without treatment. The morphometric studies showed that cilazapril increased the lumen diameter in the afferent arterioles and decreased the media-lumen ratio in a dose-dependent manner. On withdrawal of cilazapril treatment, the reduction in blood pressure persisted. Mibefradil tended to increase afferent arteriolar diameter, whereas it did not alter media-lumen ratio. The persistent effect on blood pressure was only moderate after withdrawal of mibefradil. Bosentan had no effect on renal afferent arteriolar structure or blood pressure. In conclusion, cilazapril was more effective than mibefradil in altering afferent arteriolar structure and caused the most persistent effect on blood pressure after treatment withdrawal. The association of increased afferent arteriolar diameter and lower blood pressure level after withdrawal of treatment may suggest a pathogenic role for afferent arteriolar diameter in the development of high blood pressure in SHR.
Key Words: kidney • arterioles • rats, inbred SHR • angiotensin-converting enzyme inhibitors • calcium antagonists • bosentan
This article has been cited by other articles:
 |
|
 |
|
  K. Skov, H. Eiskjaer, H. E. Hansen, J. K. Madsen, S. Kvist, and M. J. Mulvany Treatment of Young Subjects at High Familial Risk of Future Hypertension With an Angiotensin-Receptor Blocker Hypertension, July 1, 2007; 50(1): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Potenza, F. L. Marasciulo, M. Tarquinio, E. Tiravanti, G. Colantuono, A. Federici, J.-a Kim, M. J. Quon, and M. Montagnani EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1378 - E1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xue, Y.-L. Zhang, G.-S. Liu, and H. Wang A New ATP-Sensitive Potassium Channel Opener Protects the Kidney from Hypertensive Damage in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 501 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Schmidlin, M. Tanaka, A. W. Bollen, S.-L. Yi, and R. C. Morris Jr Chloride-Dominant Salt Sensitivity in the Stroke-Prone Spontaneously Hypertensive Rat Hypertension, May 1, 2005; 45(5): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chappell, P. E. Gallagher, D. B. Averill, C. M. Ferrario, and K. B. Brosnihan Estrogen or the AT1 Antagonist Olmesartan Reverses the Development of Profound Hypertension in the Congenic mRen2.Lewis Rat Hypertension, October 1, 2003; 42(4): 781 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bertram, N. Blanc-Brunat, J. Sassard, and M. Lo Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1041 - R1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Johnson, J. Herrera-Acosta, G. F. Schreiner, and B. Rodriguez-Iturbe Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension N. Engl. J. Med., March 21, 2002; 346(12): 913 - 923. [Full Text] [PDF]
|
|
|
|
 |
|
 B.I. Levy, G. Ambrosio, A.R. Pries, and H.A.J. Struijker-Boudier Microcirculation in Hypertension: A New Target for Treatment? Circulation, August 1, 2001; 104(6): 735 - 740. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Reddi, V. R. Nimmagadda, and R. Arora Effect of Antihypertensive Therapy on Renal Artery Structure in Type 2 Diabetic Rats With Hypertension Hypertension, May 1, 2001; 37(5): 1273 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. W. Bos, M. M. Demircan, J. J. Weening, R. T. Krediet, and A. C. van der Wal Renal vascular changes in renal disease independent of hypertension Nephrol. Dial. Transplant., March 1, 2001; 16(3): 537 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Skov, S. Mogensen, and M. J Mulvany Persistent effect of treatment with candesartan cilexetil on blood pressure in spontaneously hypertensive rats Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S91 - S94. [Abstract] [PDF]
|
|
|
|
|
|
R. G. Luke Hypertensive nephrosclerosis: pathogenesis and prevalence : Essential hypertension is an important cause of end-stage renal disease Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2271 - 2278. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Mulvany Vascular remodelling of resistance vessels: can we define this? Cardiovasc Res, January 1, 1999; 41(1): 9 - 13. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tanaka, O. Schmidlin, S.-L. Yi, A. W. Bollen, and R. C. Morris Jr. Genetically determined chloride-sensitive hypertension and stroke PNAS, December 23, 1997; 94(26): 14748 - 14752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mazzali, J. Kanellis, L. Han, L. Feng, Y.-Y. Xia, Q. Chen, D.-H. Kang, K. L. Gordon, S. Watanabe, T. Nakagawa, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism Am J Physiol Renal Physiol, June 1, 2002; 282(6): F991 - F997. [Abstract] [Full Text] [PDF]
|
|